Understand the source comparison
Glow Stack Protocol: Peptide Comparison
This table compares peptide options across administration, half-life, primary mechanism, and optimal stacking context. MK-677 Oral 24 hours Ghrelin receptor agonist. Sustained GH/IGF-1 elevation Evening dosing as GH-axis foundation; pairs with non-GH peptides
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This table compares peptide options across administration, half-life, primary mechanism, and optimal stacking context.
- MK-677
- Oral
- 24 hours
- Ghrelin receptor agonist. Sustained GH/IGF-1 elevation
- Evening dosing as GH-axis foundation; pairs with non-GH peptides (SLU-PP-332, KPV, Cartalax)
- Best for sustained anabolic base without injection; daily dosing for 3–6 months without desensitization
- Thymalin
- Subcutaneous
- 4–6 hours
- Thymic epithelial stimulation. T-cell differentiation
- Morning dosing in 10-day cycles; avoid stacking with other immune peptides during active cycle
- Gold standard for immune rejuvenation; pulsed cycling prevents overstimulation
- Cerebrolysin
- Intramuscular/IV
- 2.5 hours (active fragments)
- Neurotrophic factor delivery. Synaptic plasticity
- Midday dosing in 10–20 day cycles; pairs with evening GH secretagogues
- Clinical-grade nootropic with human trial data; requires injection
- Dihexa
- Subcutaneous/Oral
- 2–4 hours
- HGF receptor agonist. Synaptogenesis
- Morning/early afternoon in 1–2 week pulses; combine with non-cognitive peptides
- Extreme potency (7 orders > BDNF); short cycles with long assessment breaks
- SLU-PP-332
- 6–8 hours
- Mitochondrial biogenesis via ERRα
- Flexible timing; complements any stack without receptor competition
- Emerging research compound; metabolic enhancement without GH pathway
- Hexarelin
- 70 minutes
- GHSR-1a agonist. Acute GH pulse
- Pre-sleep dosing on non-MK-677 days; 5-on/2-off to prevent desensitization
- Powerful acute GH release but desensitizes faster than MK-677